Molecular Partners and Orano Med expand partnership adding six new therapy candidates
From GlobeNewswire: 2025-01-12 13:00:00
Molecular Partners and Orano Med have expanded their collaboration, adding six more targeted alpha therapy candidates to their pipeline, bringing the total to ten programs. The most advanced candidate, DLL3-targeted MP0712, is set to begin clinical trials in 2025. This partnership combines Molecular Partners’ Radio-DARPin Platform with Orano Med’s 212Pb supply, aiming to develop innovative radiotherapy treatments. Financial terms of the agreement were not disclosed. Molecular Partners maintains its funding guidance through 2027. Both companies are focused on advancing targeted alpha therapies to provide innovative solutions for patients.
The partnership between Molecular Partners and Orano Med highlights their commitment to developing novel radiotherapy treatments utilizing the Radio-DARPin platform. The collaboration aims to accelerate the delivery of targeted alpha therapies by leveraging Orano Med’s expertise in TAT development with 212Pb and Molecular Partners’ unique Radio-DARPin technology. The addition of six new programs to the pipeline underscores the companies’ dedication to advancing cancer treatments through innovative approaches. DLL3-targeted MP0712, the most advanced candidate, is expected to enter clinical trials in 2025. The expansion of the partnership signifies a significant step forward in the development of targeted alpha therapies.
Read more at GlobeNewswire: Molecular Partners and Orano Med expand partnership to